Cabaletta Bio, Inc., a clinical-stage biotechnology company, focuses on the discovery and development of engineered T cell therapies for patients with autoimmune diseases. Its lead product candidate is resecabtagene autoleucel, a 4-1BB co-stimulatory domain-containing fully human CD19-CAR T for the treatment of Phase 1/2 clinical trials in dermatomyositis, anti-synthetase syndrome, immune-mediated necrotizing myopathy, lupus nephritis, non-renal systemic lupus erythematosus, systemic sclerosis, and generalized myasthenia gravis. The company also develops DSG3-CAART, which is in Phase I/II clinical trial for the treatment of mucosal pemphigus vulgaris; and MuSK-CAART, an investigational cell therapy for treating patients with anti-muscle-specific kinase (MuSK) antibody positive myasthenia gravis. It has a collaboration with the University of Pennsylvania and the Children's Hospital of Philadelphia; Nanjing IASO Biotherapeutics Co., Ltd; Oxford Biomedica; Autolus Holdings (UK) Limited; and WuXi Advanced Therapies, Inc. The company was formerly known as Tycho Therapeutics, Inc. and changed its name to Cabaletta Bio, Inc. in August 2018. Cabaletta Bio, Inc. was incorporated in 2017 and is headquartered in Philadelphia, Pennsylvania.

Period	Debt/Equity
2019-12-31	0.02
2020-12-31	0.05
2021-12-31	0.07
2022-12-31	0.12
2023-12-31	0.07
2024-12-31	0.21

	A	B	C	D
1	Symbol	Price	Change	Volume
2	CABA	$3.08	+0.49%	1.17M
3
4
5

Cabaletta Bio Inc. (CABA) Debt to Equity Ratio

Debt to Equity Ratio Data

Get Cabaletta Bio Inc. Data in Excel

More CABA Financial Data